be297c26-df4c-4ae2-a117-a8c6d1cfb421
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 79
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.945 |
| 2 | 97A8E2B1-059B-4527-8FB4-116F718FFD16 | — | — | 0.945 |
| 3 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.938 |
| 4 | FBB4DAFD-11F1-498F-95C5-73D8B735465B | — | — | 0.937 |
| 5 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.931 |
| 6 | E89DB941-19C3-4CD9-9117-EAAF3B2AFD76 | — | — | 0.929 |
| 7 | B8AED170-C88C-4A86-8377-93B5D14AB334 | — | — | 0.923 |
| 8 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.923 |
| 9 | 9E5B5D00-45A2-48A9-9F57-0B4AAE9E4E25 | — | — | 0.923 |
| 10 | 27875588-7C41-49BB-A4C0-A66D72A12499 | — | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |